Allos Therapeutics, Inc. Announces Third Quarter Conference Call and Webcast.Business Editors WESTMINSTER, Colo.--(BUSINESS WIRE)--Oct. 24, 2002 Allos Therapeutics, Inc. (Nasdaq: ALTH), will hold its quarterly conference call to discuss third quarter results on Thursday, November 7, 2002, at 11:00 a.m. Eastern Time (9 a.m. Mountain Time). This call is being webcast by CCBN CCBN Central Coast Bancorp CCBN Charles County Business Network and can be accessed at Allos Therapeutics' web site at www.allos.com. The webcast is also being distributed over CCBN's Investor Distribution Network to both institutional and individual investors. Individual investors can listen to the call through CCBN's individual investor center at www.companyboardroom.com or by visiting any of the investor sites in CCBN's Individual Investor Network. Institutional investors can access the call via CCBN's password-protected event management site, StreetEvents (www.streetevents.com). About Allos Therapeutics, Inc. Allos Therapeutics, Inc. is a biopharmaceutical company focused on developing and commercializing innovative drugs for improving cancer treatments. The Company's lead clinical candidate, RSR RSR Regular sinus rhythm, see there 13 (efaproxiral), is a synthetic small molecule that enhances the diffusion of oxygen to hypoxic hypoxic a state of hypoxia. hypoxic cell sensitizers compounds that selectively sensitize hypoxic tumor cells to the effects of radiation. (oxygen deprived) tumor tissues from hemoglobin hemoglobin (hē`məglō'bĭn), respiratory protein found in the red blood cells (erythrocytes) of all vertebrates and some invertebrates. , the oxygen carrying protein contained within red blood cells Red blood cells Cells that carry hemoglobin (the molecule that transports oxygen) and help remove wastes from tissues throughout the body. Mentioned in: Bone Marrow Transplantation red blood cells . The presence of oxygen in tumors is an essential element for the effectiveness of radiation therapy and some chemotherapy agents in the treatment of cancer. By increasing the partial pressure of oxygen (pO2) in tumor tissues at the time of treatment, RSR13 has the potential to sensitize sen·si·tize v. To make hypersensitive or reactive to an antigen, such as pollen, especially by repeated exposure. hypoxic tissues and enhance the efficacy of standard radiation therapy and certain chemotherapeutic drugs. Unlike chemotherapeutics or other radiation sensitizers, RSR13 does not have to cross the blood brain barrier and enter the tumor for efficacy. For more information about the Company, please consult www.allos.com. |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion